At the news
? BULLISHIMPACT 5/10 PRESS-RELEASE filed Nov 12, 2026 at 16:05 ET
ImmuCell reported Q3 2026 net income of $953,000 ($0.10/diluted share) versus a net loss of $140,000 in Q3 2025, with product sales up 46% to $8.0 million. The company also terminated its At-The-Market offering and is negotiating a new $3 million line of credit.
- Q3 2026 product sales $8.0M, up 46% from $5.5M in Q3 2025
- Net income $953,000 ($0.10/diluted) vs net loss $140,000 in Q3 2025
- Gross margin improved to 44.2% from 42.9%
- Adjusted EBITDA $1.9M vs $0.8M in Q3 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access